For patients whose cancer has relapsed following, or was resistant to these, now-conventional chemotherapy and antibody treatments, the use of HER2 targeting small molecule tyrosine kinase inhibitors and antibody-drug conjugates in the second and subsequent lines of therapy can produce further improvements [1–5]. The gene discussed is ERBB2; the disease is cancer.